Iradimed CORP Form 4 insider transactions

IRADIMED Corp. Director Monty K. Allen acquired 905 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership.

IRADIMED's Chief Financial Officer, John Glenn, exercised restricted stock units and performance-based restricted stock units on December 7, 2025, subsequently selling shares to cover tax obligations.

IRADIMED Corp. Director and 10% Owner James B. Hawkins sold 3,000 shares of common stock for a weighted average price of $96.6125 per share on December 9, 2025.

IRADIMED CEO Roger E. Susi sold 5,000 shares of common stock on December 8, 2025, through a pre-arranged 10b5-1 trading plan.

IRADIMED Director James B. Hawkins converted 1,197 restricted stock units into common stock, increasing his direct beneficial ownership.

IRADIMED Director Hilda Scharen-Guivel converted 1,197 restricted stock units into common stock, increasing her direct beneficial ownership.

IRADIMED Director Monty K. Allen converted 1,197 restricted stock units into common stock, increasing his direct beneficial ownership to 21,095 shares.

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $463,700 through a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, reported the sale of 5,000 shares of common stock on November 24, 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Director James B Hawkins sold 2,999 shares of common stock in multiple transactions on November 20, 2025, under a pre-arranged trading plan.

IRADIMED Corp's CEO, Roger E. Susi, sold 5,000 shares of common stock in pre-planned transactions on November 18, 2025.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $426,048 through a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Corp's CFO, John Glenn, sold 10,651 shares of common stock for a weighted average price of $84.5143 in a pre-planned transaction.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $413,282 through a pre-arranged 10b5-1 trading plan.

IRADIMED CEO Roger E. Susi sold 5,000 shares of common stock on October 27, 2025, through a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on October 21, 2025, through a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Director Hilda Scharen-Guivel converted 1,767 restricted stock units into common stock, increasing her direct beneficial ownership to 6,496 shares.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on October 13, 2025, through a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on October 6, 2025, under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED CEO Roger E. Susi sold 4,900 shares of common stock on October 1, 2025, through a pre-arranged 10b5-1 trading plan.

IRADIMED Corporation's Director, Joe E. Kiani, received a grant of 2,095 restricted stock units, which will vest in three equal annual installments starting September 23, 2026.

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for $71.2581 per share under a pre-arranged trading plan.

IRADIMED CEO Roger E. Susi sold 5,000 shares of common stock for approximately $356,000 through a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Corp. Director Monty K. Allen has filed a Form 4 indicating a pre-planned sale of 1,102 common shares at $69.1 per share, effective August 6, 2025.

IRADIMED Corporation's Chief Financial Officer, John Glenn, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

John Glenn, CFO of Iradimed, files an amended Form 4 to correct a previous error regarding the disposal of 5,796 Restricted Stock Units (RSUs).

James B. Hawkins, a director at Iradimed Corporation, filed an amended Form 4 to correct an overstatement of directly owned shares reported in a previous filing.

John Glenn, CFO of Iradimed Corp, reports the vesting of restricted stock units and subsequent stock transactions.

Chief Commercial Officer of Iradimed Corp, Jeff Chiprin, was granted restricted stock units and performance-based restricted stock units on December 11, 2024.

Director Anthony Vuoto of Iradimed Corporation received 1,811 restricted stock units under the company's 2023 Equity Incentive Plan.